In addition, multiple therapeutic approaches targeting neutrophils have emerged, with several reagents entering clinical trials, such as the CXCR1/2 inhibitor SX-682 for metastatic melanoma (NTC03161431), from which OtoNP+ NPC patients might benefit. This evidence concerns the gene CXCR1 and nasopharyngeal carcinoma.